We identified two genetic variants in TPCN2 that are significantly associated with prostate cancer susceptibility and disease recurrence in patients with prostate cancer, which necessitates investigating the causal mechanisms underlying the role of these genetic variants in prostate cancer development. This evidence concerns the gene TPCN2 and prostate carcinoma.